➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Johnson and Johnson
Boehringer Ingelheim
Baxter

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

NORPACE CR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Norpace Cr, and when can generic versions of Norpace Cr launch?

Norpace Cr is a drug marketed by Gd Searle Llc and is included in one NDA.

The generic ingredient in NORPACE CR is disopyramide phosphate. There are nineteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the disopyramide phosphate profile page.

Drug patent expirations by year for NORPACE CR
Drug Prices for NORPACE CR

See drug prices for NORPACE CR

Recent Clinical Trials for NORPACE CR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mayo ClinicPhase 3
MedtronicPhase 3

See all NORPACE CR clinical trials

Pharmacology for NORPACE CR
Drug ClassAntiarrhythmic

US Patents and Regulatory Information for NORPACE CR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655-001 Jul 20, 1982 RX Yes No   Start Trial   Start Trial   Start Trial
Gd Searle Llc NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655-002 Jul 20, 1982 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Johnson and Johnson
Boehringer Ingelheim
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.